Ergoteles’s Xeris Biopharma Holdings XERS Stock Holding History

Ergoteles’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,200	Closed	-$65K	–	2053
2022 Q1	$65K	Buy	+25,200	New	+$61.6K	﹤0.01%	1146

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ergoteles's XERS Position: Q2 2022 in Review

Ergoteles sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 25,200 shares — an estimated $65K sold.

Ergoteles first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $65K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

Ergoteles reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
Ergoteles sold 25,200 Xeris Biopharma Holdings shares in Q2 2022, an estimated $65K.
Ergoteles first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
Ergoteles's Xeris Biopharma Holdings position peaked at $65K in Q1 2022.
103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.